AR116024A1 - Métodos de tratamiento de enfermedades neurodegenerativas - Google Patents
Métodos de tratamiento de enfermedades neurodegenerativasInfo
- Publication number
- AR116024A1 AR116024A1 ARP190102440A ARP190102440A AR116024A1 AR 116024 A1 AR116024 A1 AR 116024A1 AR P190102440 A ARP190102440 A AR P190102440A AR P190102440 A ARP190102440 A AR P190102440A AR 116024 A1 AR116024 A1 AR 116024A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- treatment
- neurodegenerative diseases
- dyrk1a
- ask1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos de tratamiento o prevención de enfermedades, trastornos o condiciones relacionadas con ASK1 o DYRK1A, que comprenden administrar a un sujeto que lo necesita un inhibidor dual de ASK1 o DYRK1A o sus sales y solvatos farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724574P | 2018-08-29 | 2018-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR116024A1 true AR116024A1 (es) | 2021-03-25 |
Family
ID=69644584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190102440A AR116024A1 (es) | 2018-08-29 | 2019-08-27 | Métodos de tratamiento de enfermedades neurodegenerativas |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210213006A1 (es) |
AR (1) | AR116024A1 (es) |
TW (1) | TW202024020A (es) |
WO (1) | WO2020046975A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022165250A1 (en) * | 2021-01-28 | 2022-08-04 | University Of Florida Research Foundation, Incorporated | Treating disorders associated with dyrk1a dysfunction |
WO2024020458A1 (en) * | 2022-07-20 | 2024-01-25 | Seal Rock Therapeutics, Inc. | Method of treating organ diseases or disorders with ask1 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
AR067585A1 (es) * | 2007-07-19 | 2009-10-14 | Schering Corp | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa |
EP2346860B1 (en) * | 2008-10-08 | 2012-09-19 | Bristol-Myers Squibb Company | Pyrrolone melanin concentrating hormone receptor-1 antagonists |
TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
US8791112B2 (en) * | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
WO2019136025A1 (en) * | 2018-01-02 | 2019-07-11 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
-
2019
- 2019-08-27 TW TW108130668A patent/TW202024020A/zh unknown
- 2019-08-27 US US17/271,883 patent/US20210213006A1/en active Pending
- 2019-08-27 WO PCT/US2019/048388 patent/WO2020046975A1/en active Application Filing
- 2019-08-27 AR ARP190102440A patent/AR116024A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20210213006A1 (en) | 2021-07-15 |
TW202024020A (zh) | 2020-07-01 |
WO2020046975A1 (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
MX2021006901A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
CL2020000911A1 (es) | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd | |
PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
ECSP21016032A (es) | Inhibidores de la interacción proteína-proteína keap1-nrf2 | |
MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
CL2018003260A1 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos. | |
MX2020013163A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
MX2021013318A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
AR116024A1 (es) | Métodos de tratamiento de enfermedades neurodegenerativas | |
ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
ZA201907101B (en) | Methods of preventing or treating ophthalmic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |